GASTRIC CANCER

Findings presented at the 2022 Gastrointestinal Cancers Symposium warrant the need for new treatments that attack HER2-low advanced gastric cancer.

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

In an interview with Targeted Oncology, Ronan Kelly, MD, discussed the most recent updates seen in these patient populations and what research aims to further examine.

New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

ADP-A2M4CD8, an autologous T-cell therapy, showed promising antitumor activity in several solid tumor types including ovarian, gastric, and urothelial cancer.

Orphan drug designation has been granted by the FDA to XMT-2056 for the treatment of patients with gastric cancers.

CMG90 is the only drug in its class to have received fast-track status to date. Prior to its fast track status, the drug was granted orphan drug designation by the FDA.

During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.

TST001 has shown to be safe in ongoing trials alone or in combination with chemotherapy and displayed encouraging anti-tumor activity signals in gastric cancer and other solid tumor patients expressing CLDN18.2.

In an interview with Targeted Oncology following the tweet chat, Yelena Y. Janjigian, discussed the key takeaways from the discussion and highlighted the biomarkers and standard of care for the patient in this case.

Ryan Sugarman, MD, discusses the design and purpose of the CheckMate 649 trial for gastroesophageal cancers, gastric cancer, and esophageal adenocarcinoma.

In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.

Findings show DKN-01, tislelizumab, and capecitabine/oxaliplatin (CAPOX) combination to be well tolerated and have encouraging clinical activity as frontline treatment of patients with advanced gastroesophageal adenocarcinoma.

In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Results presented during the 2022 Gastrointestinal Cancers Symposium showed that 58.6% of evaluable patients experienced complete regression and fibrosis with no tumor cells.

Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

A study of cinrebafusp alfa is underway to evaluate its safety and efficacy in combination with other therapies in patients with gastric or gastroesophageal junction cancers.

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.

Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.

The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer.

In Western patients with HER2-positive gastric/gastroesophageal junction cancer Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate.

In patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression, the addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes.

Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer were seen with Linagliptin plus atezolizumab.

The FDA has granted an orphan drug designation to TST001, an anti-Claudin18/2 monoclonal antibody, for the treatment of gastric cancer or gastroesophageal junction.

Pembrolizumab has been voluntarily withdrawn from the North American market as a treatment option for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

“We observed much more deeper responses and more meaningful responses [in the treatment arm] compared with the placebo arm, in which 15% of the population had deep responses of ≥ 80%."

The combination of paclitaxel and GSK2636771 showed encouraging antitumor activity and a manageable toxicity profile and in patients with PTEN-deficient advanced gastric cancer who progressed after first line chemotherapy.